written on 24.06.2014
Tags:
,

Tumor Genome Profiling: The Way of the Future or TMI?

TAGS: ,

The most frequent argument about whether targeted therapies are worth it is about money – in the crudest terms whether the slim survival benefit of such drugs justifies their fat price tag. The American Society of Clinical Oncology (ASCO) 2014 has declared value to be one theme of this year’s annual meeting. But at the […]

Latest Report